Bend Research has won two new US patents covering the technology that increases the oral bioavailability of low-solubility drugs.
The patents protect compositions and processes for making spray-dried dispersions (SDDs) made with an active pharmaceutical ingredient and hydroxypropyl methylcellulose acetate succinate (HPMCAS), a polymer also known as hypromellose acetate succinate.
Bend Research CEO Rod Ray said, "Our goal is to provide a growing patent portfolio for our customers' use in protecting their investments in advancing low-solubility compounds to the market."
The HPMCAS SDDs facilitate the use of lower drug doses to achieve effective therapies for low-solubility drugs. The technology is designed to work by sustaining high concentrations of drug in patients' gastrointestinal tracts.
The patents both titled Solid Pharmaceutical Dispersions with Enhanced Bioavailability are the result of work funded by Pfizer and are assigned to Bend Research.
